Anti-cyclic citrullinated peptide autoantibodies in IgM rheumatoid factor-positive patients

The use of anti-CCP antibodies affords good clinical efficiency and modifies the pre-test probability of the occurrence of RA in patients with IgM rheumatoid factor higher than 20 IU/mL.